Valemetostat clinical trials
Also written DS-3201.
Includes 10 studies of Valemetostat tosylate.
How each study uses valemetostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the valemetostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
17 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 10
Daiichi Sankyo (5) · M.D. Anderson Cancer Center (3) · Daiichi Sankyo Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · The Lymphoma Academic Research Organisation (1) · Alliance for Clinical Trials in Oncology (1) · University of Alabama at Birmingham (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Carboplatin (1) · Cabazitaxel (1) · Abiraterone Acetate (1) · Abiraterone (1) · Enzalutamide (1) · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test valemetostat.
- Dec 2026DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersPhase 1 · M.D. Anderson Cancer Center
- Jan 2027A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerPhase 1 · Memorial Sloan Kettering Cancer Center
- Sep 2027A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses valemetostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Valemetostat Tosylate
- A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT06807632Written as Valemetostat
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Daiichi SankyoNCT07244341Written as Valemetostat
- A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCRecruitingPhase 1/2University of Alabama at BirminghamNCT06294548Written as Valemetostat
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.RecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07303387Written as Valemetostat Tosylate
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingPhase 2Daiichi SankyoNCT04703192Written as Valemetostat Tosylate
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05683171Written as Valemetostat
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingPhase 1/2Daiichi SankyoNCT06644768Written as valemetostat tosylate
- Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05633979Written as Valemetostat
- DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04388852Written as Valemetostat
- DS-3201b in Participants With LymphomasActive, not recruitingPhase 1Daiichi Sankyo Co., Ltd.NCT02732275Written as DS-3201b
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04842877Written as Valemetostat tosylate
- Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnPhase 1/2National Cancer Institute (NCI)NCT05879484Written as valemetostat
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT04102150Written as Valemetostat Tosylate
- DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung CancerTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03879798Written as DS-3201b
- DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedPhase 1Daiichi SankyoNCT03110354Written as DS-3201b
- Study of Single-dose DS-3201b in Participants With Hepatic ImpairmentCompletedPhase 1Daiichi SankyoNCT04276662Written as DS-3201b
Given beside what is tested · 2 — valemetostat is usual care or a partner of the new treatment
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruitingPhase 1Daiichi SankyoNCT06244485Written as Valemetostat tosylate
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingPhase 1/2CelgeneNCT03930953Written as Valemetostat
Codes
What other systems call valemetostat · ClinicalTrials.gg INT015161
- UNII (FDA) 60RD0234VEVALEMETOSTATOne source FDA
- NCI Thesaurus C127114ValemetostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 60RD0234VE | VALEMETOSTAT | One source FDA |
| NCI Thesaurus | C127114 | Valemetostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.